Revised SPC: Nexplanon (etonogestrel) 68 mg implant for subdermal use
electronic Medicines Compendium - eMC
electronic Medicines compendium
16 January 2020
SPC updated to include post market surveillance reports of undesirable effects from treatment including; respiratory disorders (e.g. cough and haemoptysis) and haematoma following insertion or removal of the implant.